Table 1.
Patients’ characteristics and results (retrospective study).
| Group | Urolithiasis | Healthy | p-Value 5 | |||
|---|---|---|---|---|---|---|
| Primary a (n = 94) | Recurrence b (n = 16) | Volunteers c (n = 157) | a vs. b | b vs. c | a vs. c | |
| Sex (male/female) | 55/39 | 6/10 | 57/100 | 0.3553 | >0.9999 | 0.019 |
| median (IQR 1) | median (IQR 1) | median (IQR 1) | ||||
| Age (years) | 67 (60–73) | 67 (49–71) | 46 (37–57) | 0.9333 | 0.0003 | <0.0001 |
| uFL-OPN 2 (ng/mL/mg protein) |
14.4 (11.1–191.1) |
13.3 (9.8–93.3) |
56,392 (30,271–115,517) |
>0.9999 | <0.0001 | <0.0001 |
| Gal3C-S-OPN 3 /uFL-OPN 2 (MFI 4/uFL-OPN 2) |
52.3 (4.7–111.6) |
72.0 (21.5–144.2) |
0.007 (0.003–0.020) |
>0.9999 | <0.0001 | <0.0001 |
1 IQR, Interquartile range; 2 uFL-OPN, Urinary full-length-osteopontin; 3 Gal3C-S-OPN, Gal3C-S lectin reactive osteopontin; 4 MFI, mean fluorescence intensity; 5 p-value, Kruskal–Wallis test. a, Primary stone forming urolithiasis patients; b, Recurrence stone forming urolithiasis patients; c, Healthy volunteers.